Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study

Szu-Min Hsieh, Shan-chwen Chang, Hao-Yuan Cheng, Shin-Ru Shih, Chia En Lien
doi: https://doi.org/10.1101/2021.12.01.21267115
Szu-Min Hsieh
1Department of Internal Medicine, Division of Infectious Diseases, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hsmaids@hotmail.com allenlien@medigenvac.com
Shan-chwen Chang
1Department of Internal Medicine, Division of Infectious Diseases, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao-Yuan Cheng
2Medigen Vaccine Biologics Corporation, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin-Ru Shih
3Research Centre for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia En Lien
2Medigen Vaccine Biologics Corporation, Taipei, Taiwan
4Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hsmaids@hotmail.com allenlien@medigenvac.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The waning antibody levels after immunization and the emergence of SARS-CoV-2 variants of concern (VoC) negatively impact the vaccine-induced neutralization of SARS-CoV-2. In this extension to the phase 1 clinical study, we report the antibody durability until 180 days after the second dose of MVC-COV1901, and examined the reactogenicity and immunogenicity followed by a booster shot MVC-COV1901 administered to 45 healthy adults from 20 to 49 years of age on day 209. Adverse reactions after the booster dose were mostly mild and comparable to that of the first two doses. Neutralizing antibodies remained detectable on day 209 at 59.4, 79.4, and 113.2 (IU/mL) for low dose (LD), middle dose (MD), and high dose (HD) groups, respectively. At four weeks after the booster dose, neutralizing titers increased to 1719.6, 818.3, and 1345.6 for LD, MD, and HD groups, respectively. Our data also showed that three doses of MVC-COV1901-induced antibodies were still effective, albeit lowered neutralizing titers, against the Omicron variant.

Competing Interest Statement

H.-Y.C. and C.E.L. are employees of Medigen Vaccine Biologics Corporation and have received grants from the Taiwan Centers of Disease Control, Ministry of Health and Welfare. S.-M.H., S.-C.C., and S.-R.S. declared no conflict of interest. All authors have reviewed and approved of the final version of the manuscript.

Clinical Trial

NCT04487210

Funding Statement

Medigen Vaccine Biologics Corporation and Taiwan Centers for Disease Control, Ministry of Health and Welfare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research Ethics Committee of National Taiwan University Hospital gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Revision of abstract; Revision of introduction to include the recent variants; Expanded the methods section to include more details; Added Omicron neutralization data to the results and discussion section.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 04, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study
Szu-Min Hsieh, Shan-chwen Chang, Hao-Yuan Cheng, Shin-Ru Shih, Chia En Lien
medRxiv 2021.12.01.21267115; doi: https://doi.org/10.1101/2021.12.01.21267115
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study
Szu-Min Hsieh, Shan-chwen Chang, Hao-Yuan Cheng, Shin-Ru Shih, Chia En Lien
medRxiv 2021.12.01.21267115; doi: https://doi.org/10.1101/2021.12.01.21267115

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (862)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1757)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10317)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1681)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3853)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)